Allogene Therapeutics’ Post

It’s days like today that remind me just how much we can achieve for patients with lung cancer when we innovate with purpose, lead with science and put patients first.   Johnson & Johnson Innovative Medicine has announced positive topline results from the Phase 3 MARIPOSA study in patients with EGFR-mutated non-small cell lung cancer - the first chemo-free regimen to show meaningful, durable effects, with a trend in overall survival.   This landmark study has the potential to set a future standard of care in the first-line setting, where a glaring unmet need remains.   We are a bold team on a bold mission to truly transform the treatment of lung cancer!    Read more here: https://prn.to/3LCMqA8   #MyCompany #Oncology #LungCancer #Future #Innovation

Recent CRI Findings Published in ASCO Journal: Nearly 60% of centers reported activating NCI-sponsored studies within 90 days but only 9% reported meeting a 90-day activation timeline for industry sponsored studies. Shrink your activaton timelines - let us show you how to accelerate timelines and increase capacity. Talk to Vitalief today! https://lnkd.in/eedSp8YN https://lnkd.in/g9Wh7KE3 #clinicalresearch #clinicaltrials #trialactivation #timetoactivation

AACI Findings from a 2023 survey of cancer center clinical trials offices were recently published in JCO Oncology Practice. The study, "North American Cancer Center Clinical Research Capacity and Benchmarking in the Post-Pandemic Era," “Conclusion: Contemporary benchmarks for CCTO operations through this survey demonstrate larger staff sizes, larger budgets, more trials supported, but fewer patients enrolled to interventional treatment trials in comparison with 2018. These data shine a critical light on the increasing complexity of cancer clinical trials, the importance of external funding sources, and necessary operational efficiency upgrades to provide cutting-edge cancer research and care.” https://lnkd.in/e6z99YY2 #CancerResearch #Oncology #ClinicalTrials

Get ready to revolutionize cancer care! Our newest blog, "𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲," delves into the groundbreaking advancements transforming the landscape of cancer treatment. #PrecisionMedicine #OncologyInnovation #futureofhealthcare

📰 Drug Discovery World featured POLB 001 in the introduction to its Global Cancer Research Guide, which outlined it as an exciting clinical development in addressing cancer immunotherapy-induced CRS, with potential to enable broader use of cancer immunotherapies in an outpatient setting. Click below to read more (starting page 39) https://lnkd.in/gtSZijU9 #POLB #Oncology

🔬 Excited for #ASCO24! 🎉 Mark your calendars for Tuesday, June 4, 2024, at 11am EST as we dive into the heart of cancer drug development. ASCO is THE conference for groundbreaking insights, and we're thrilled to bring you the latest from the frontline. Join us online as our experts decode the data readouts, revealing the strengths, weaknesses, and future directions of cancer treatment pipelines. Don't miss out on the biggest news shaping the oncology landscape today! Stay ahead of the curve with Endpoints.#Oncology #CancerResearch #EndpointsAtASCO #news #trends

Lung Cancer Treatment: Beyond Chemotherapy At MGM Cancer Institute, we offer a comprehensive array of strategies: 1. Chemotherapy 2. Targeted Therapy 3. Immunotherapy Meet Dr. M A Raja, Senior Consultant in Medical Oncology and Director of Oncology Services at MGM Cancer Institute, as he unveils the diverse pathways for managing lung cancer. Discover these options in our enlightening video. Ready to embark on a personalized treatment journey? Reach out to our specialist here or call +91 44 4251 5151. #MGMCancerInstitute #MGMCares #FightCancer #CancerTreatment #CancerCare #TreatmentOptions #MedicalScience #LungCancer”

As the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concludes, we reflect on the innovative discoveries unveiled this year. In a new article, Henar Hevia, Senior Director and EMEA Therapeutic Area Lead for Oncology, goes one step further, delving into the past, present as well as the future of lung cancer care, since the ground-breaking identification of EGFR mutations in lung cancer, and how this has paved the way for improved patient outcomes. Read it here: https://lnkd.in/eH5tTg5G #ASCO24 #PrecisionMedicine #LungCancer #InFrontOfCancer

In 2023, liver cancer will account for approximately 2.1% of new cancer cases in the U.S.--but approximately 4.8% of cancer deaths. While rare, over 40,000 Americans are diagnosed with this cancer each year--and cases have been on the rise. With continued research into precision oncology treatments, improved diversity in clinical trials, and better screening rates (especially for HBV and HCV), we can improve survival rates for this deadly disease. #LiverCancer #BileDuctCancer #LCAM #HCC #Cholangiocarcinoma

World Cancer Research Day, September 24th, is observed to encourage all oncology stakeholders to actively participate in cancer research to reduce cancer cases, increase survival rates, and improve the quality of life for patients with cancer. Carevive, a digital oncology company, is committed to improving patient experience by capturing real-world data to enable cancer programs to meet the requirements of an evolving reimbursement landscape and life science companies to gain new insights about the patient journey. Join us in commemorating #WorldCancerResearchDay and meet with us at ASCO Quality in Boston next month. https://lnkd.in/dddCeNbK Keri Collette Mordecai Kramer Aaron Galaznik Bruno Lempernesse #WorldCancerResearchDay #smartdata #patientexperience #workingtogether #cancer #patientengagement #oncology #epros #patientexperiencedata